RE: Interesting part of RNS info that was missed, bridging cohort phase 1a to phase 1B12 Dec 2024 22:14
Im not going to argue metal head up to each individual to decide how they interpret an RNS. Here’s chat GPTs thoughts and conclusions make of it what you will.
“The statement suggests that Avacta has observed anti-tumor activity in both the dose escalation and Recommended Dose for Expansion (RDE) cohorts during Phase 1. Here’s the reasoning behind this interpretation:
1. Encouragement from Anti-Tumor Activity:
The mention of being “encouraged by the anti-tumor activity” explicitly indicates that measurable evidence of tumor response (such as reductions in tumor size, stable disease, or other markers of efficacy) was observed in these earlier cohorts.
2. Inclusion of RDE Cohorts:
The phrase does not limit the anti-tumor activity to only the dose escalation phase but includes the RDE cohorts. Since the RDE cohorts aim to further validate findings at the optimal dose, it would be logical that such activity was noted at this stage as well.
3. Purpose of Expansion Cohorts:
Expansion cohorts are designed to build on earlier observations, focusing on specific tumor types to refine efficacy and safety data. This implies confidence in the anti-tumor activity seen thus far, including in the RDE cohorts, as the foundation for further exploration.
Conclusion:
It’s reasonable to infer that Avacta has observed anti-tumor activity in the RDE cohorts. This is significant as it suggests the optimal dose is both safe and shows promising signs of efficacy, supporting the rationale for moving into disease-specific expansion cohorts in Phase 1b.”
